ttprizm

PriZm Therapeutics is a private, late-stage clinical biotech company focused on ultra-rare pediatric orphan diseases. The company is advancing SRW101, a novel synthetic triiodothyronine analogue, for monocarboxylate transporter 8 deficiency, also known as Allan-Herndon-Dudley syndrome. PriZm positions itself as a translational rare-disease company built around expertise in endocrinology, drug development, and orphan indications. Its current business appears concentrated on developing and clinically advancing this lead program rather than a broad multi-asset platform. The company is headquartered in Chandler, Arizona and has emphasized regulatory designations including Orphan Drug and Rare Pediatric Disease designation for SRW101.